Edition:
United States

Novus Therapeutics Inc (NVUS.OQ)

NVUS.OQ on NASDAQ Stock Exchange Capital Market

4.77USD
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
$4.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
23,931
52-wk High
$8.61
52-wk Low
$3.13

Chart for

About

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a... (more)

Overall

Beta: 0.36
Market Cap(Mil.): $44.94
Shares Outstanding(Mil.): 9.42
Dividend: --
Yield (%): --

Financials

  NVUS.OQ Industry Sector
P/E (TTM): -- 30.48 32.69
EPS (TTM): -1.42 -- --
ROI: -49.01 13.04 12.72
ROE: -49.27 14.99 14.85

BRIEF-Novus Therapeutics Reports Q1 Loss Per Share $0.36

* NOVUS THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 11 2018

BRIEF-Novus Therapeutics Reports Quarterly Loss Per Share Of $0.36

* NOVUS THERAPEUTICS SAYS HAD $22.5 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31 - SEC FILING Source text: (https://bit.ly/2rza3AD) Further company coverage:

May 11 2018

BRIEF-Novus Therapeutics Reports Q4 Loss Per Share $0.30

* Q4 LOSS PER SHARE $0.30 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Apr 02 2018

BRIEF-Novus Therapeutics Qtrly Loss Per Share $0.30

* QTRLY LOSS PER SHARE $0.30 Source text for Eikon: Further company coverage:

Apr 02 2018

Earnings vs. Estimates